FDA accepts NDA and grants priority review for Pixclara
Filed with ASX · · 3 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Telix Files Form 20-F Registration Statement for Nasdaq ADS
- Telix Q3 2024 Revenue and Business Update
- Telix to Acquire RLS for US Manufacturing and Distribution
- Telix Submits NDA for TLX101-CDx Brain Cancer Imaging Agent
- Telix 1H 2024 Results Release
Later from Telix Pharmaceuticals
- CMS payment improvement decision for radiopharma diagnostics
- Telix Adds FAP-Targeting Theranostic Candidates to Pipeline
- Presentation to Accompany FAP-Targeting Acquisition
- TLX to Acquire Next-Gen Therapeutics and Biologics Platform
- Presentation to Accompany Biologics Platform Acquisition
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals